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Introduction
It has been suggested that glucose, the brain’s primary fuel 
source, regulates food intake (1). Although glucose injections 
into the CNS reduce food intake, glucose is preferred to other 
types of food by rodents and humans (2–4). Therefore, a mech-
anism to detect glucose in food and promote the intake of glu-
cose-rich foods is likely to exist. The regulation of glucose intake 
has been studied extensively (5, 6). A system regulating glucose 
intake, driven by hedonic responses generated in the limbic sys-
tem, has been identified (7). Dopamine is thought to be impor-
tant in the hedonic response to glucose (8). Evidence suggests 
that nonhedonic nontaste systems are important in regulating 
glucose intake (9) and that metabolism of glucose is an impor-
tant factor (10). However, a nontaste-dependent homeostatic 
mechanism within the hypothalamus or elsewhere in the brain 
has proved elusive.
Glucokinase is a member of the hexokinase family of enzymes, 
which phosphorylates glucose to form glucose-6 phosphate (11). 
Glucokinase is expressed in the liver, pancreas, and CNS (11, 12). 
Glucokinase is expressed in 2 isoforms: a hepatic form expressed 
in the liver and a neuroendocrine form expressed in the pancreas 
and CNS (13). The 2 isoforms are produced by the utilization of dif-
ferent promoters. The isoforms have the same kinetic properties 
but different functions (13). Within the β cells and glucose-sensi-
tive neurons glucokinase is part of a glucose-sensing system (14). 
The mechanism used for the glucose-sensing system is thought 
to be similar in both β cells and neurons (14). Glucose entry into 
the cell is via the GLUT-2 transporter (15). Metabolism of glucose 
by glucokinase results in closure of the ATP-sensitive potassium 
(KATP) channels. This results in depolarization of the cell and 
release of hormone via a calcium-dependent mechanism.
In the pancreas and liver, glucokinase has an important 
role in regulating glucose homeostasis (11). Its role in the CNS 
is less clear. In the hypothalamus, glucokinase is expressed in 
regions, including the arcuate nucleus, ventromedial nucleus 
(VMN), paraventricular nucleus (PVN), and lateral hypotha-
lamic area (LHA), which regulate energy homeostasis and are 
part of a CNS glucose-sensing system (14, 16, 17). In the VMN, 
glucokinase is involved in mediating the hormonal counterregu-
latory responses to hypoglycemia and does not regulate energy 
homeostasis (18, 19). While a role for hypothalamic glucokinase 
in regulating energy homeostasis has been proposed, it has never 
been confirmed (12, 14). We hypothesized that glucokinase in the 
hypothalamic arcuate nucleus was involved in the regulation of 
energy homeostasis. We found that increased arcuate nucleus 
glucokinase activity increased food intake and weight gain in 
rats. It also increased glucose intake in preference to other food 
types. These effects were mimicked by intra-arcuate administra-
tion of glibenclamide, which blocks the KATP channel. Converse 
effects were obtained by reducing glucokinase activity in the 
arcuate nucleus and with intra-arcuate injection of diazoxide, a 
KATP channel activator. We identified a likely mechanism involv-
ing P/Q voltage-gated calcium channels, NPY release, and action 
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To determine the long-term effect of increased glucokinase 
in the arcuate nucleus, we used recombinant adeno-associated 
virus (rAAV) to overexpress the neuroendocrine isoform of glu-
cokinase (rAAV-GK) in this nucleus. The enzymatic activity of 
the construct was tested in vitro in HEK293 cells. Cells trans-
fected with rAAV-GK had significantly increased glucokinase 
activity compared with cells transfected with the control virus 
expressing GFP (rAAV-GFP) (Figure 1C). We stereotactically 
injected rAAV-GK into the arcuate nucleus of adult male Wistar 
rats (referred to herein as iARC-GK rats) and rAAV-GFP into the 
arcuate nucleus of control rats (referred to herein as iARC-GFP 
rats). In keeping with other studies using similar protocols (22), 
glucokinase activity was increased specifically in the arcuate 
nucleus of iARC-GK rats by 2.03 ± 0.30–fold compared with that 
in controls (Figure 1D). Glucokinase activity was not altered in 
either the VMN or the PVN (Figure 1D). Consistent with this, 
increased glucokinase expression was specifically localized to 
the hypothalamic arcuate nucleus in iARC-GK rats (Supple-
mental Figure 2, A and B). Expression of GFP, as detected by 
immunocytochemistry, was also limited to the arcuate nucleus 
in iARC-GFP animals (Supplemental Figure 2C). These results 
confirm the validity of iARC-GK rat as a model of increased arcu-
ate nucleus glucokinase activity.
Compared with controls, iARC-GK rats had increased cumu-
lative food intake, gained more weight, and had increased body 
fat when fed a standard chow diet (at 33 days, cumulative food 
intake: iARC-GFP, 1,094.3 ± 22.39 g; iARC-GK, 1,194.1 ± 24.92 g; 
via neuropeptide Y (NPY) Y1 and Y5 receptors. These data sup-
port a role for arcuate glucokinase acting through the KATP chan-
nel in the regulation of dietary glucose intake.
Results
Glucokinase activity in the arcuate nucleus is regulated by fasting. 
To determine whether glucokinase activity is regulated by nutri-
tional state and in which hypothalamic regions this occurred, 
we measured glucokinase activity in hypothalamic nuclei of 
male Wistar rats following a 24-hour fast. Fasting increased 
glucokinase activity specifically in the arcuate nucleus 1.71-fold 
compared with controls. Glucokinase activity in the VMN and 
PVN was not altered (Figure 1A and Supplemental Figure 1, A 
and B; supplemental material available online with this article; 
doi:10.1172/JCI77172DS1). The arcuate nucleus plays a pivotal 
role in the metabolic sensing and control of food intake (20). 
Therefore, alterations in the activity of the glucokinase may rep-
resent a physiological appetite control mechanism that is influ-
enced by nutritional state.
Increased glucokinase activity in the arcuate nucleus increases 
food intake and body weight gain. To investigate the role of arcuate 
nucleus glucokinase activity on food intake, we increased glucok-
inase activity in the arcuate nucleus. Injection of the glucokinase 
activator, compound A (CpdA) (17, 21), into the arcuate nucleus of 
adult male Wistar rats increased food intake during the first hour 
after administration compared with control injections (control, 
0.38 ± 0.13 g; CpdA, 1.07 ± 0.27 g; mean ± SEM) (Figure 1B).
Figure 1. Effect increased arcuate nucleus glucokinase activity on food intake. (A) Arcuate nucleus glucokinase activity in ad libitum chow–fed and 
24-hour–fasted male Wistar rats (n = 8). (B) Normal chow intake 1 hour after intra-arcuate injection of 0.5 nmol CpdA or vehicle (control) in male Wistar 
rats (n = 10). (C) Glucokinase activity in HEK293 cell lysates after transfection with either rAAV-GFP or rAAV-GK (n = 6). (D) Glucokinase activity in arcuate 
nucleus (ARC), VMN, and PVN of male Wistar rats following intra-arcuate injection of either rAAV-GFP (iARC-GFP, white bars) or rAAV-GK (iARC-GK, 
black bars) (n = 8–11). (E) Cumulative food intake and (F) weight changes in iARC-GFP (black squares) and iARC-GK (white squares) rats after recovery 
from surgery (n = 12 iARC-GFP; n = 15 iARC-GK). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus corresponding control 
values; #P < 0.0001 versus all other groups.
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Increased glucokinase activity in the arcuate nucleus increases 
glucose intake in preference to chow. We hypothesized that arcu-
ate nucleus glucokinase selectively stimulates intake of glu-
cose-rich foods in preference to other foods. To investigate 
whether increased glucokinase activity in the arcuate nucleus 
increased glucose intake in preference to chow, we measured 
the intake of glucose and chow when ad libitum access to both 
was available. In this setting, injection of a glucokinase acti-
vator into the arcuate nucleus resulted in a 2.52 ± 0.51–fold 
increase in 2% w/v glucose intake in the first hour after injec-
tion (Figure 2D), which is consistent with our previous finding 
(Figure 2A). In contrast to when chow was presented alone (Fig-
ure 1B), CpdA did not increase chow intake when it was pre-
sented alongside glucose (vehicle, 1.69 ± 0.4 3g; CpdA, 1.43 ± 
0.70 g) (Figure 2E).
Similarly, in iARC-GK rats, 24-hour intake of 2%, 10%, and 
20% w/v glucose was significantly increased (Figure 2F and Sup-
plemental Figure 4, A and D). Twenty-four hour chow intake and 
total energy intake (derived from both chow and glucose) were 
not different between the 2 groups when glucose was available 
in addition to chow (Figure 2, G and H, and Supplemental Figure 
4, B, C, E, and F). When chow was presented alone, chow intake 
cumulative weight gain: iARC-GFP, 151.67 ± 8.86 g; iARC-GK, 
175.33 ± 4.87 g; body fat: iARC-GFP, 22.12% ± 1.73%; iARC-GK, 
28.0% ± 1.62%) (Figure 1, E and F, and Supplemental Figure 
3A). Lean mass, brown adipose tissue (BAT) weight, BAT Ucp1 
mRNA expression, and glucose and insulin levels were unaltered 
(Supplemental Figure 3, B–H). Two-hour food intake following a 
48-hour fast was no different between the 2 groups (Supplemen-
tal Figure 3I). These data suggest that increased arcuate nucleus 
glucokinase activity increases food intake and bodyweight and 
support a role for arcuate nucleus glucokinase in the control of 
energy homeostasis.
Increased glucokinase activity in the arcuate nucleus increases glu-
cose intake but not fructose intake. Since glucokinase is part of the 
glucose-sensing mechanism, we tested whether increased arcuate 
nucleus glucokinase activity affected the intake of glucose or fruc-
tose, a closely related sugar, which is not a substrate for glucoki-
nase (23). Both pharmacologic and genetic activation of arcuate 
nucleus glucokinase increased intake of 2% and 10% w/v glucose 
solution (Figure 2, A–C). In contrast, intake of fructose solution 
was not affected (Figure 2, B and C). These data suggest that, in 
terms of sugar intake, arcuate nucleus glucokinase activity may 
specifically regulate glucose intake.
Figure 2. Effect of increased arcuate nucleus glucokinase activity on glucose intake. (A) 2% w/v glucose solution intake 1 hour after intra-arcuate injec-
tion of CpdA or control in rats (n = 7). Twenty-four hour intake of (B) 2% w/v and (C) 10% w/v glucose and fructose solutions in iARC-GFP (white bars) and 
iARC-GK rats (black bars) (n = 8). (D) 2% w/v glucose solution intake and (E) food intake 1 hour after intra-arcuate injection of CpdA or vehicle in rats with 
ad libitum access to 2% w/v glucose solution and normal chow (n = 7). (F) 2% w/v glucose solution intake, (G) food intake, and (H) energy intake in iARC-
GFP (black circles) and iARC-GK (white squares) rats during a 24-hour feeding study, with ad libitum access to 2% w/v glucose solution and normal chow 
intake (n = 7). (I) Food intake in iARC-GFP (black circles) and iARC-GK (white squares) rats (n = 7) during a 24-hour feeding study, with ad libitum access to 
normal chow diet only. (J) 10% w/v glucose, (K) food intake with normal chow, (L) total energy intake, and (M) weight changes in iARC-GFP (black circles) 
and iARC-GK (white squares) rats with ad libitum access to normal chow diet and 10% w/v glucose given 4 weeks after rAAV microinjection (n = 8). Data 
are presented as mean ± SEM *P < 0.05, **P < 0.01, ***P < 0.001.
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Decreased glucokinase activity in the arcuate nucleus decreases 
food intake and glucose intake. To examine the physiological role of 
arcuate glucokinase in the regulation of energy homeostasis and 
glucose consumption, we used rAAV encoding antisense glucok-
inase (rAAV-ASGK), which has previously shown to be effective 
at reducing glucokinase activity in vivo (24). The activity of the 
construct was tested in vitro in Hep g2 cells. Cells transfected with 
rAAV-ASGK had markedly reduced glucokinase activity com-
pared with that of cells transfected with rAAV-GFP (Figure 3A). 
We stereotactically injected rAAV-ASGK into the arcuate nucleus 
of adult male Wistar rats (referred to herein as iARC-ASGK rats); 
iARC-GFP rats were used as the control. Glucokinase activity was 
decreased specifically in the arcuate nucleus of iARC-GK rats to 
approximately 50% of that of control iARC-GFP rats (Figure 3B). 
Glucokinase activity was not altered in the VMN or the PVN (Fig-
ure 3B). iARC-ASGK rats consumed less food (at 33 days, food 
intake: iARC-GFP, 1,039 ± 17.9 g; iARC-ASGK, 994 ± 14.1 g) (Figure 
3C), and they also gained less weight, although this did not reach 
statistical significance (iARC-GFP, 153.9 ± 6.0 g; iARC-ASGK, 
139 ± 6.2 g) (P = 0.06), when fed a standard chow diet compared 
with controls (Figure 3D). We tested the effect of reduced glucok-
and therefore energy intake were increased in iARC-GK rats com-
pared with controls (iARC-GFP, 25.86 ± 1.01 g; iARC-GK, 29.46 ± 
1.27 g) (Figure 2I). This suggests that the increase in chow intake 
produced by glucokinase activation was driven by an increased 
appetite for glucose.
To determine whether this effect was sustained long term, 
iARC-GK and iARC-GFP rats were given ad libitum access to 10% 
w/v glucose and standard chow. Increased arcuate nucleus glu-
cokinase activity resulted in increased glucose intake (at 31 days, 
iARC-GFP, 2,812.9 ± 91.89 ml; iARC-GK, 3,337.1 ± 131.39 ml) (Fig-
ure 2J). The previously observed increase in food intake, energy 
intake, and body weight gain in iARC-GK rats that occurred with 
chow alone did not occur when a glucose solution was available 
in addition to the chow diet (at 31 days, food intake: iARC-GFP, 
691.94 ± 19.41 g; iARC-GK, 682.14 ± 22.84 g; energy intake: iARC-
GFP, 14.41 ± 0.33 MJ; iARC-GK, 15.07 ± 0.42 MJ; weight gain: 
61.00 ± 4.17 g; iARC-GK, 66.25 ± 6.12 g) (Figure 2, K–M). These 
data support a role for arcuate glucokinase in selectively regulat-
ing glucose intake and support our hypothesis that the orexigenic 
effect of increasing arcuate nucleus glucokinase activity is the 
result of an increased drive to consume glucose.
Figure 3. Effect of decreased arcuate nucleus glucokinase activity on food and glucose intake. (A) Glucokinase (GK) activity in Hep G2 cell lysates 
after transfection with either rAAV-GFP or rAAV-ASGK (n = 6). (B) Glucokinase activity in arcuate nucleus, VMN, and PVN of male Wistar rats following 
intra-arcuate injection of either rAAV-GFP (iARC-GFP) or rAAV-ASGK (iARC-ASGK). (C) Cumulative food intake and (D) weight changes in iARC-GFP (black 
diamonds) and iARC-ASGK (white diamonds) rats after recovery from surgery (n = 11). (E) 2% w/v glucose solution intake, (F) food intake, and (G) energy 
intake in iARC-GFP (black diamonds) and iARC-ASGK (white diamonds) rats during a 24-hour feeding study, with ad libitum access to 2% w/v glucose 
solution and normal chow intake (n = 11). (H) 10% w/v glucose, (I) food intake with normal chow, (J) total energy intake, and (K) weight changes in iARC-
GFP (black diamonds) and iARC-ASGK (white diamonds) rats, with ad libitum access to normal chow diet and 10% w/v glucose given 4 weeks after rAAV 
microinjection (n = 11). Data presented as mean ± SEM *P < 0.05, ***P < 0.001 versus corresponding control values.
Downloaded from http://www.jci.org on April 15, 2015.   http://dx.doi.org/10.1172/JCI77172
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 4 1jci.org   Volume 125   Number 1   January 2015
was significantly increased 4 hours after glibenclamide injection 
compared with that after control injections when glucose was pre-
sented alone (Figure 4B). When both chow diet and glucose were 
present, only glucose intake was increased following glibencl-
amide injection, compared with that after control injection (1.93 ± 
0.57 relative to control), with chow intake unaffected (0.97 ± 0.19 
relative to control) (Figure 4, C and D).
Conversely, injection of diazoxide into the arcuate nucleus 
inhibited food intake when chow was presented alone compared 
with that after control injections (Figure 4E and Supplemental 
Figure 5A). Glucose intake was also reduced following injection 
of diazoxide compared with that after control injections (Figure 
4F and Supplemental Figure 5B). However, when both glucose 
and chow were available, only the consumption of glucose was 
decreased following diazoxide injection, whereas that of chow 
remain unchanged (Figure 4, G and H, and Supplemental Figure 
5, C and D).
The role of KATP channels in mediating the increased glucose 
intake stimulated by glucokinase activation in the arcuate nucleus 
was investigated by coadministration of diazoxide and CpdA into 
the arcuate nucleus in fed animals. As before, injection of CpdA 
increased intake of glucose, and this increased glucose intake 
was blocked by coadministration of diazoxide (Figure 4I). Under 
the conditions used, diazoxide given alone did not affect glucose 
intake when administered alone (Figure 4I). These data are in 
accord with KATP channels having a role in transducing the effects 
of arcuate nucleus glucokinase on glucose appetite.
Effects of arcuate nucleus glucokinase on hypothalamic AMPK, 
ACC, and FAS. We investigated possible mechanisms by which 
increased arcuate nucleus glucokinase activity may be exert-
ing its effects on food and glucose intake. Increasing arcuate 
inase activity in the arcuate nucleus on 24-hour glucose intake in 
the presence of ad libitum access to normal chow. In this setting, 
intake of 2% w/v glucose solution was reduced in the iARC-ASGK 
group compared with that in the iARC-GFP group throughout the 
24-hour period (Figure 3E) and intake of chow and total energy 
intake were not different between the groups (Figure 3, F and G).
To determine whether this effect was sustained long term, 
iARC-ASGK and iARC-GFP rats were given ad libitum access to 
10% w/v glucose and standard chow. Decreased arcuate nucleus 
glucokinase activity resulted in significantly lower glucose intake 
(at 33 days, iARC-GFP, 3,674 ± 173.8 ml; iARC-ASGK, 3,090 ± 
263.8 ml) (Figure 3H). The previously observed decrease in food 
intake and body weight gain in iARC-ASGK rats that occurred with 
chow alone did not occur when a glucose solution was available 
in addition to the chow diet (at 33 days, food intake: iARC-GFP, 
684.8 ± 21.2 g; iARC-ASGK 711.0 ± 22.2 g; energy intake: iARC-
GFP, 16.82 ± 0.37 MJ; iARC-ASGK, 16.36 ± 0.49 MJ; weight gain: 
iARC-GFP 66.6 ± 3.3 g; iARC-ASGK, 71.4 ± 6.1 g) (Figure 3, I–K).
Pharmacologic modulation of the KATP channel in the arcuate 
nucleus mimic the effects of altered glucokinase activity. One signal-
ing mechanism downstream of glucokinase is the KATP channel. 
We therefore hypothesized that inhibition of KATP channels may 
mediate the effect of arcuate nucleus glucokinase on food intake 
and glucose appetite. To investigate whether arcuate glucoki-
nase may be acting via inhibiting the KATP channels, either the 
KATP channel inhibitor, glibenclamide, or the KATP channel acti-
vator, diazoxide, was injected into the arcuate nucleus of Wistar 
rats. Four hours after injection of glibenclamide, food intake was 
increased compared with that after control injections when chow 
was available alone (2.22 ± 0.77 relative to control) (Figure 4A). 
Similarly, 2% w/v glucose intake (2.73 ± 0.99 relative to control) 
Figure 4. Effect of activating and inhibiting arcuate nucleus KATP channels on food intake and glucose appetite. (A) Chow intake relative to that of 
control-treated rats 4 hours after intra-arcuate injection of 2 nmol glibenclamide (Glib) or vehicle (control) in rats (n = 12). (B) 2% w/v glucose solution 
intake relative to that of control-treated rats 4 hours after intra-arcuate injection of 2 nmol glibenclamide or vehicle in rats (n = 11). (C) Chow intake and 
(D) 2% w/v glucose intake relative to that of control-treated rats 4 hours after intra-arcuate injection of 2 nmol glibenclamide or vehicle in rats with ad 
libitum access to 2% w/v glucose and normal chow (n = 10). (E) Chow intake relative to that of control-treated rats 1 hour after intra-arcuate injection of 
1 nmol diazoxide (Dia) or vehicle in rats (n = 9). (F) 2% w/v glucose intake relative to that of control-treated rats 1 hour after intra-arcuate injection of 1 
nmol diazoxide or vehicle in rats (n = 9). (G) Chow intake and (H) glucose intake relative to that of control-treated rats 1 hour after intra-arcuate injection 
of 1 nmol diazoxide or vehicle in rats with ad libitum access to 2% w/v glucose and normal chow (n = 9). (I) 2% w/v glucose solution intake 1 hour after 
intra-arcuate injection of vehicle CpdA or 1 nmol diazoxide administered alone (control) or followed by injection of 0.5 nmol CpdA in rats (n = 10). Data are 
presented as mean ± SEM. *P < 0.05; ***P < 0.001 versus control; †††P < 0.001 versus CpdA vehicle injected.
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nucleus glucokinase activity did not affect either expression or 
activity of hypothalamic adenosine monophosphate–activated 
protein kinase (AMPK), a key cellular energy sensor that is 
influenced by cellular ATP levels (ref. 25 and Figure 5, A and 
B). In addition, there was no difference in expression of the 
metabolic sensing enzyme acetyl CoA carboxylase in iARC-GK 
animals compared with that in controls (ref. 26 and Figure 5A). 
There was a small increase in fatty acid synthase expression in 
iARC-GK animals compared with that in controls (Figure 5A). 
This enzyme catalyzes the synthesis of long-chain fatty acids 
and modulates food intake (27).
The effects of glucokinase on glucose intake are dependent upon 
calcium channel activity. To investigate whether the effects of arcu-
ate nucleus glucokinase activity were dependent upon calcium 
channel activity specific calcium channel blockers were used. 
Either nifedipine, specific for L-type calcium channels, or ω-aga-
toxin IVA, specific for P/Q-type channels, was injected into the 
arcuate nucleus, followed by injection of CpdA and measurement 
of intake of 2% w/v glucose. Injection of nifedipine alone did not 
alter glucose intake at 1 hour (Figure 5C) or at subsequent time 
points (Supplemental Figure 6A), and it did not have any effect 
on glucose intake stimulated by CpdA at either 1 hour (Figure 5C) 
Figure 5. Effect of increased arcuate nucleus glucokinase on NPY and α-MSH and effect of NPY antagonist and calcium channel blockade on 
glucokinase activator–stimulated glucose intake. (A) Hypothalamic Ampk, Acc, and Fas expression in iARC-GFP and iARC-GK rats (n = 9). (B) 
Hypothalamic AMPK activity in hypothalami from iARC-GFP and iARC-GK rats (n = 10). (C) 2% w/v glucose solution intake 1 hour after intra-arcuate 
injection of vehicle ω-agatoxin-IVA (Agatox) or nifedipine (Nifed) and subsequent injection of CpdA or control in rats (n = 15). (D) Glucose-induced 
NPY release from hypothalamic slices of iARC-GFP or iARC-GK rats (n = 7 iARC-GFP; n = 8 iARC-GK). (E) Glucose-induced α-MSH release from hypo-
thalamic slices of iARC-GFP or iARC-GK rats (n = 7 iARC-GFP; n = 8 iARC-GK). (F) NPY release from rat hypothalamic slices, following treatment with 
CpdA, glibenclamide, or diazoxide (n = 10–12). (G) α-MSH release from rat hypothalamic slices, following treatment with CpdA, glibenclamide, or 
diazoxide (n = 6–9). (H) NPY release from rat hypothalamic slices, following treatment with CpdA or diazoxide alone and in combination (CpdA+Dia) 
(n = 10–12). (I) 2% w/v glucose solution intake 1 hour after intra-peritoneal injection of vehicle CGP-71683 (CGP) or BMS-193885 (BMS) and subse-
quent intra-arcuate injection of CpdA or control in rats (n = 14). Data are presented as mean ± SEM. *P < 0.05 versus corresponding control values; 
#P < 0.05 versus control values from 8 mM and 15 mM glucose; **P < 0.00001 versus corresponding CpdA-injected group; †††P < 0.0001 versus 
vehicle CpdA-injected group; ***P < 0.0001.
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or subsequent time points (Supplemental Figure 6A). Injection of 
ω-agatoxin IVA alone did not affect glucose intake either at 1 hour 
(Figure 5C) or subsequent time points (Supplemental Figure 6A). 
In contrast, injection of ω-agatoxin IVA completely blocked the 
stimulatory effects of CpdA on glucose intake at 1 hour (Figure 5C) 
and up to 8 hours after injection (Supplemental Figure 6A). These 
data suggest that the effects of glucokinase on glucose intake are 
dependent upon P/Q-type calcium channels.
Effects of altered glucokinase activity on NPY release. Release of 
NPY from ex vivo hypothalamic slices in response to increasing 
glucose concentrations was altered in iARC-GK animals com-
pared with that in iARC-GFP controls. Treatment of hypothalamic 
slices from iARC-GFP rats with increasing concentrations of glu-
cose resulted in a decrease in NPY release (Figure 5D). In con-
trast, treatment of hypothalamic slices from iARC-GK rats with 
increasing concentrations of glucose did not affect NPY release. 
Release of α-melanocyte–stimulating hormone (α-MSH) from ex 
vivo hypothalamic slices from either iARC-GFP or iARC-GK rats 
was not affected by changes in glucose concentration (Figure 5E).
A similar response was seen when hypothalamic slices were 
treated with either CpdA, a glucokinase activator, or glibencl-
amide, which blocks KATP channels. Treatment with either of 
these 2 pharmacologic agents increased NPY release from ex vivo 
hypothalamic slices (Figure 5F). In contrast, treatment of ex vivo 
hypothalamic slices with diazoxide, which activates KATP channels, 
reduced NPY release (Figure 5F). Release of α-MSH from hypo-
thalamic slices was not altered by any treatment (Figure 5G). The 
increased release of NPY from the hypothalamic slices stimulated 
by glucokinase activation appears to be dependent on closure of 
the KATP channel, since treatment of ex vivo slices with diazoxide 
blocked the effect of CpdA (Figure 5H). These data indicate that 
the effects of arcuate nucleus glucokinase on energy homeostasis 
may be mediated by the orexigenic neurotransmitter NPY.
The effects of glucokinase activation on glucose intake are blocked 
by NPY receptor antagonists. To investigate whether NPY was phys-
iologically important in the effects of arcuate nucleus glucokinase 
activity on glucose intake, NPY receptor antagonists were used. 
Either BMS-193885, a NPY Y1–specific antagonist, or CGP-71683, 
a NPY Y5–specific antagonist, was injected intraperitoneally, fol-
lowed by injection of CpdA into the arcuate nucleus. Injection of 
BMS-193885 alone did not affect intake of glucose at 1 hour (Fig-
ure 5I) or at any subsequent time point. Injection of BMS-193885 
did attenuate the CpdA-stimulated intake of glucose at 1 hour 
(Figure 5I) and all time points up to 8 hours (Supplemental Figure 
6B). Similarly injection of CGP-71683 alone did not affect glucose 
intake at 1 hour (Figure 5I) or at any subsequent time point (Sup-
plemental Figure 6B). However, injection of CGP-71683 did atten-
uate the CpdA-stimulated intake of glucose at 1 hour (Figure 5I) 
and all time points up to 8 hours (Supplemental Figure 6B). These 
data support a physiological role for NPY in the effects of arcuate 
glucokinase in the regulation of glucose consumption via both the 
Y1 and the Y5 receptor.
Discussion
It has been suggested that glucose sensors, such as glucokinase, 
have a role in the hypothalamic regulation of food intake (1, 14). 
Increased glucokinase activity has been postulated but not demon-
strated to reduce food intake as part of a glucostatic control sys-
tem. We found that glucokinase activity increased in the arcuate 
nucleus following a fast. Expression of glucokinase is regulated by 
fasting in a tissue-specific manner. Expression of hepatic glucok-
inase is reduced by fasting (28), while expression of the neuroen-
docrine form of glucokinase in the pancreas is unaltered by fasting 
(28). In contrast, expression of the neuroendocrine form of glucok-
inase in the hypothalamus is increased by fasting (29). The mech-
anism underlying the differences in the regulation of expression is 
unclear; however, it is likely to be the result of differences in the 
promoter sequence used and the combination of transcription fac-
tors expressed in each tissue. In addition to this, regulation of glu-
Figure 6. Schematic representation of the proposed mechanism by which 
arcuate nucleus glucokinase regulates glucose intake. (A) Representation 
when only one diet is available. When mixed food is ingested, glucose is 
released and enters the arcuate nucleus. Metabolism of the glucose by glu-
cokinase results in closure of the KATP channel and increased NPY release. 
The increase in NPY stimulates further food intake. The normal satiety 
process would terminate the feeding response. (B) Representation when a 
rich source of glucose is available in addition to normal diet. If pure glucose 
or a food high in glucose is available, the positive feedback loop will be 
more active. This will result in a preferential intake of the food with a high 
glucose concentration and reduced intake of the mixed diet.
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in animals with increased glucokinase activity is in part driven by 
an increased physiological drive for glucose consumption. This 
hypothesis is further supported by the finding that, in iARC-GKAS 
animals with reduced glucokinase activity in the arcuate nucleus, 
glucose intake was reduced but chow intake was unaffected when 
both were freely available.
Intracerebroventricular injection of glucose has been estab-
lished to decrease food intake as part of the system of metabolic 
regulation of food intake (14, 19, 34). Our data would seem con-
trary to this effect. However, there are several glucose-sensing 
regions in the brain, both within and outside the hypothalamus. It 
is likely that activation of these regions following injection of glu-
cose into the brain is substantially different to that resulting from 
glucose ingestion.
The metabolic regulation of food intake by glucose is well 
established (14, 19, 34, 35), while homeostatic taste-independent 
mechanisms promoting glucose intake have been postulated 
but not demonstrated in mammals. Such a mechanism would 
increase intake of foods rich in glucose. Throughout evolutionary 
history, such foods have been difficult to obtain, and glucose is 
a vital nutrient for some tissues, including the brain. Therefore, 
a mechanism to maximize intake of glucose-rich foods when 
available would be advantageous. A similar mechanism has been 
found recently in invertebrates (36). In rodents and humans, glu-
cose intake leads to a coordinated response between homeostatic 
and hedonic pathways regulating sensing, reward, and feeding 
behavior (7, 37). This study suggests that, within the arcuate 
nucleus, glucokinase is an integral part of the homeostatic CNS 
glucose-sensing mechanism that regulates glucose appetite. 
Our data does not exclude the possibility that other nuclei that 
express glucokinase within the hypothalamus or brain stem have 
a role in regulating glucose intake or homeostasis, as the effect of 
altered glucokinase activity in these regions was not tested. Data 
from invertebrate, rodent, and human studies suggest that food 
intake is regulated around a fixed macronutrient ratio (38, 39). 
Our results suggest that arcuate nucleus glucokinase regulates 
the set point for glucose and that altering arcuate nucleus glucok-
inase activity alters the set point for glucose consumption (40). 
Such a set point would explain the normalization in body weight 
gain in the iARC-GK and iARC-GKAS animals given access to 
glucose. The iARC-GK animals were able to sate their glucose 
appetite without intake of other nutrients. The glucose solution 
has a lower energy content per unit of glucose and thus the over-
all energy intake of these rats was reduced compared with those 
that only had access to chow. This same effect was observed with 
the controls in the rAAV-GKAS study. This mechanism would be 
specific for glucose, since other monosaccharides, for example, 
fructose, are not substrates for glucokinase and thus would not 
activate this pathway. Therefore, the maintenance of a glucose 
source in the diet of obese individuals may be important to satiate 
glucose appetite, given that hypothalamic glucokinase expression 
is elevated in animal models of obesity (32). This homeostatic sys-
tem may explain the effects of foods with different glycemic index 
values on weight loss (41). Foods that have a high glycemic index 
value, which release large amounts of glucose quickly, would acti-
vate the arcuate glucokinase pathway. This would encourage fur-
ther food intake. Foods with a low glycemic index value would not 
cokinase occurs at a transcriptional level. It has been demonstrated 
recently that glucokinase activity in the hypothalamus is regulated 
by glucokinase regulatory protein (GKRP) (30). GKRP regulates 
glucokinase activity by binding to it and inactivating it by seques-
tering it within the nucleus (31). In the liver, the binding of GKRP 
to glucokinase is increased by hypoglycemia and fasting, resulting 
in reduced glucokinase activity, which is reduced in response to 
these stimuli. However, in the hypothalamus, binding of GKRP to 
glucokinase is inhibited by fasting and increased by hyperglycemia 
(30). Therefore, glucokinase activity in the hypothalamus would be 
increased with fasting, in line with our findings.
Injection of the glucokinase activator, CpdA, into the arcuate 
nucleus increased food intake. This is opposite from the effect 
proposed by the glucostatic hypothesis of food intake, although 
it is consistent with the increase in glucokinase activity detected 
following a fast. Many orexigenic agents demonstrate increased 
activity or expression in response to fasting, whereas anorexic 
agents demonstrate the opposite response (20). To investigate 
whether this effect was sustained, rAAV-GK was stereotactically 
injected into the arcuate nucleus of adult male iARC-GK rats. On 
a chow diet, iARC-GK animals consumed more food than iARC-
GFP animals, in accord with the findings following pharmaco-
logic activation. To investigate the physiological importance of 
this, we reduced arcuate nucleus glucokinase activity by injecting 
rAAV-ASGK into the arcuate nucleus of iARC-ASGK rats. On a 
chow diet, iARC-ASGK animals consumed less food than iARC-
GFP animals. Together, these data suggest that increased arcuate 
nucleus glucokinase activity may constitute an orexigenic signal. 
This is consistent with previous work revealing increased hypo-
thalamic glucokinase mRNA expression in diet-induced obese 
and obese-prone rats (32). Previous studies have failed to demon-
strate an orexigenic effect of glucokinase (19). However, they did 
not specifically target the arcuate nucleus. In addition, they used 
methods that do not alter glucokinase activity specifically and that 
are known to alter food intake via other mechanisms (33). These 
effects on food intake are unlikely to be secondary to changes in 
circulating glucose or insulin levels, since neither fasting nor fed 
glucose and insulin levels were changed in the iARC-GK animals 
compared with those in the iARC-GFP animals.
Since glucokinase is an integral part of the glucose-sensing 
mechanism in the pancreas and specialized neurons (14, 17), we 
hypothesized that arcuate nucleus glucokinase activity may specif-
ically regulate the consumption of glucose rather than just energy. 
This was tested by allowing the rats access to a source of pure glu-
cose, either alone or in the presence of chow. Following injection 
of CpdA, intake of glucose was increased in iARC-GK rats com-
pared with controls, while intake of fructose was unaffected. This 
suggests that the increase in food intake depends on the presence 
of glucose in the food. When glucose and chow were presented 
together, glucose intake was enhanced, while chow intake was 
unaffected by injection of CpdA. We found a similar effect in long-
term studies comparing iARC-GK animals with iARC-GFP ani-
mals. In this situation, in contrast to our previous results when only 
chow was available, there was no difference in either chow intake 
or body weight between the 2 groups, while glucose intake was 
increased in the iARC-GK group compared with that in the con-
trols. This supports the hypothesis that the increase in food intake 
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Injection of the L-channel blocker nifedipine was without effect 
on CpdA-stimulated glucose intake. P/Q channels are expressed 
presynaptically throughout the CNS and are important in neu-
rotransmitter release (53). Activity of these channels has been 
shown previously to mediate the release of NPY from hypotha-
lamic slices (54).
A possible cellular mechanism underlying the changes in 
food and glucose intake is increased activity of arcuate NPY neu-
rons, since there were changes in release of NPY in response to 
glucose from ex vivo hypothalamic slices from iARC-GK rats. As 
has been reported previously (55), increasing glucose concentra-
tions in the artificial CSF (aCSF) resulted in reduced NPY release 
from control hypothalami. In contrast, there was no decrease in 
NPY release from iARC-GK hypothalami with increasing glucose 
concentrations. These results were mimicked by the treatment 
of ex vivo hypothalamic slices with either CpdA, a glucokinase 
activator, or glibenclamide, which blocks KATP channels. Both of 
these treatments resulted in increased NPY release from hypotha-
lamic explants. Conversely, treatment of hypothalamic slices with 
diazoxide, which opens KATP channels, reduced NPY release and 
blocked the release of NPY stimulated by CpdA. A role for NPY in 
mediating this effect is supported by the finding that the increase 
in glucose intake stimulated by injection of CpdA into the arcu-
ate nucleus could be attenuated by the administration of either a 
specific NPY Y1 receptor or NPY Y5 receptor antagonist. This sug-
gests that NPY acting on both the Y1 and Y5 receptors is involved 
in the regulation of glucose intake (16, 48). NPY has been shown to 
preferentially increase carbohydrate intake compared with other 
dietary constituents (56). These findings also fit with the increased 
NPY expression, but unaltered POMC expression, in mice with 
targeted deletion of Kir6.2, a component of KATP channel, suggest-
ing that the KATP channel may play a role in the regulation of NPY 
signaling in the arcuate nucleus (51). The finding of Parton et al. 
that transgenic mice expressing KATP channels unresponsive to 
ATP in POMC neurons had normal body weight (57) further sup-
ports this potential mechanism.
It is therefore plausible that food with high levels of glucose 
causes increased activation of arcuate nucleus NPY neurons, via glu-
cokinase, KATP channels, and P/Q voltage-gated calcium channels, 
promoting further intake of that food in a positive feedback loop 
(Figure 6). This system would promote the intake of glucose-rich 
foods above that of those containing lower levels of glucose.
Overall, these results suggest that a requirement for glucose, 
rather than calories alone, partly drives food intake and that arcuate 
nucleus glucokinase can regulate this specific intake of glucose. In 
the absence of a source of pure glucose, the increased physiological 
drive for glucose, resulting from greater glucokinase activity in the 
arcuate nucleus, drives the intake of mixed nutrient foods. This hypo-
thalamic system may form part of the postingestive reward pathway 
of glucose (7, 58) or form a separate homeostatic regulatory system 
regulating glucose appetite, analogous to that described recently 
in invertebrates (36). A role in taste-driven intake is less likely, as 
this is thought to be more responsive to fructose and sweeteners 
(59), which do not appear to activate this glucokinase-based glu-
cose-sensing system, maximizing intake of what was until recently 
a rare resource. Evidence supports the existence of this pathway in 
humans. Patients with mutations that decrease glucokinase activ-
activate this system, and so further intake would not be stimu-
lated. It is possible that the recent rise in fructose consumption in 
Western-type diets may not satiate the glucose appetite, resulting 
in consumption of more calories (42).
Possible downstream signaling mechanisms were exam-
ined. The expression and activity of AMPK in the hypothalamus 
was unaffected by increased glucokinase activity in the arcuate 
nucleus. This suggests that AMPK is not an important mediator 
of the observed changes in food and glucose intake and increas-
ing arcuate nucleus glucokinase activity does not change cellular 
energy availability (25). This is not surprising, since, as in β cells, 
energy production via glycolysis is dependent upon hexokinase I 
and not glucokinase (hexokinase IV). A slight increase in hypotha-
lamic fatty acid synthase expression occurred in iARC-GKS rats. 
This may be a part of the mechanism underlying the increased 
food and glucose intake observed in the iARC-GK rats (27). 
The increase in FAS expression could be the result of increased 
ChREBP activation (43), driven by increased glucose-6-phosphate 
concentrations (44). Although activation of ChREBP would also be 
expected to increase ACC expression (43), this was not observed.
The subcellular localization and close proximity of gluco-
kinase and membrane-bound KATP channels may allow glucoki-
nase and KATP channels to function as a glucose-sensing complex 
(14). This would allow glucokinase to alter local ATP levels and 
change KATP channel activity, without affecting cellular ATP. Such 
compartmentalization of glycolytic enzymes, glycolysis, and ATP 
production has been demonstrated in a variety of cells, includ-
ing neuronal cells (45, 46). Injection of the KATP channel inhibitor 
glibenclamide resulted in the same response as increased glucok-
inase activity in the arcuate nucleus. Injection of diazoxide, a KATP 
channel activator, produced the opposite effect. In addition coad-
ministration of diazoxide blocked the increase in glucose intake 
stimulated by CpdA. These results are supportive of a role for KATP 
channels in the actions of glucokinase in the arcuate nucleus. KATP 
channels are expressed in a small number of neurons, which do 
not express glucokinase (16). It is possible that the effects of glib-
enclamide and diazoxide on food and glucose intake are being 
mediated by these neurons rather than glucokinase-expressing 
neurons. However, given the effects that closely parallel those 
of increased glucokinase activity in the arcuate nucleus and the 
well-characterized coupling between glucokinase and KATP chan-
nels (16, 17, 32, 47, 48), KATP channels appear a likely mechanism 
for transducing the effects of glucokinase on glucose appetite via 
a mechanism analogous to glucose-stimulated insulin release in 
the pancreas (14). These results are in keeping with activation 
of hypothalamic KATP channels by leptin (49, 50) and the obser-
vation that mice with targeted deletion of Kir6.2 have increased 
food intake (51). These findings also have important implications 
for the potential use of glucokinase activators and sulfonylureas 
in the treatment of type 2 diabetes. The increased food intake in 
response to arcuate nucleus glibenclamide administration could 
explain the increase in body weight seen in patients treated with 
sulfonylurea class agents (52).
The mechanism linking glucokinase to increased glucose 
intake is also likely to require activity of P/Q calcium channels. 
Injection of the specific P/Q channel blocker ω-agatoxin IVA com-
pletely blocked the increase in glucose intake stimulated by CpdA. 
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ization to the arcuate nucleus. In all animals, expression of glucok-
inase was found to be localized to the arcuate nucleus. Brains from 
one group of rats injected with rAAV-GFP were subject to either in 
situ hybridizations for expression of WPRE (n = 12), a component of 
the rAAV construct, or immunocytochemistry for GFP (n = 2). In all 
of these animals, expression was found to be limited to the arcuate 
nucleus. This process was repeated in a second group of animals 
injected with rAAV-GKAS or rAAV-GFP. The brains of all of these 
animals were subject to in situ hybridization for WPRE expression. 
In all of these animals, expression was found to be limited to the 
arcuate nucleus.
Cannulation. Intra-arcuate cannulation was performed as pre-
viously described (22). Cannulas (Plastics One) were stereotaxically 
implanted unilaterally into the arcuate nucleus. At the end of the 
injection studies, cannula placement was confirmed histologically in 
all animals. One microliter of Indian ink was injected via the cannula. 
The brains were removed and fixed in 4% formaldehyde, dehydrated 
in 40% sucrose, and frozen in isopentane cooled in liquid nitrogen. 
Brains were sliced into 15-μm coronal sections on a cryostat (Bright), 
and correct arcuate nucleus placement was determined by microscopy 
according to the position of the Indian ink. All cannula were correctly 
targeted to the arcuate nucleus.
Injection of pharmacologic agents. Rats received intra-arcuate injec-
tions at between 09:30 and 10:30 hours with either drug or vehicle 
control on 2 separate days, 72 hours apart. Rats were fasted overnight 
for studies when diazoxide was administered alone; all other studies 
were in ad libitum–fed animals. All compounds were administered in 
a 1 μl volume over a period of 1 minute. Doses were based on previous 
experiments (18, 65, 66). Data are presented as food intake and glu-
cose intake relative to those in corresponding rats treated with control 
during the crossover study.
Calcium channel studies. Rats received intra-arcuate injections 
at between 09:30 and 10:30 hours, with study days being at least 72 
hours apart. First, rats received an intra-arcuate injection of 5 nmol 
nifedipine, 1 μg ω-agatoxin IVA, or saline in random order. Fifteen 
minutes later, they received an intra-arcuate injection of either 0.5 
nmol CpdA or vehicle in random order, and glucose intake was sub-
sequently measured. All compounds were administered in a 1-μl 
volume over a period of 1 minute. Doses were based on previous 
experiments (67–69).
NPY antagonist studies. Rats received injections at between 09:30 
and 10:30 hours, with study days being at least 72 hours apart. First, 
rats received an intra-peritoneal injection of 10 mg/kg BMS-193885, 
10 mg/kg CGP-71683, or vehicle in a volume of 100 μl in random 
order; the antagonists were chosen as they are able to cross the blood-
brain barrier. Fifteen minutes later, they received an intra-arcuate 
injection of 5 nmol CpdA or vehicle in random order, and glucose 
intake was subsequently measured. Intra-arcuate injections were 
administered in a 1-μl volume over a period of 1 minute. Doses were 
based on previous experiments (70, 71).
Glucokinase activity assays. Sections 880-μm thick were cut from 
frozen brains using a freezing Shandon sled microtome and mounted 
on slides. Slides were kept on dry ice. Arcuate nucleus, VMN, and PVN 
were removed using a 22-gauge neuro punch (Fine Science Tools) (64). 
Nuclei were homogenized in 200 μl ice-cold buffer containing 0.0107 
M MgCl2, 5 mM sodium EDTA, 0.15 M KCl, and 0.07% w/v 2-mercap-
toethanol. The homogenate was centrifuged at 16,000 g for 40 minutes 
ity have reduced body weight (60). Conversely, patients who have 
mutations associated with increased activity of the neuroendocrine 
form of glucokinase have increased body weight (61).
Our results suggest that arcuate nucleus glucokinase is acting 
as part of a glucose-sensing system, analogous to that in the β cell, 
as part of a central macronutrient regulatory system. This glucose-
sensing system regulates glucose appetite and energy homeostasis. 
Glucose from food enters arcuate nucleus neurons by GLUT-2 and 
is phosphorylated by glucokinase to glucose-6-phosphate, which 
is linked to closure of KATP channels; this induces neuronal depo-
larization and entry of calcium via P/Q calcium channels, leading 
to release of NPY. Increased arcuate nucleus glucokinase activity 
could lead to a positive energy balance and increased preference 
for glucose. Diet-induced obese and diet-induced obese–prone 
rats have increased arcuate nucleus glucokinase mRNA expres-
sion, suggesting that this system may play a role in the develop-
ment of obesity (32). This mechanism may explain the observation 
that diets high in carbohydrate are associated with weight gain in 
mice (62) and why low glycemic index diets produce weight loss 
(41). It also provides a possible CNS mechanism to explain the 
often-described phenomena of the “sweet tooth” and carbohy-
drate craving, particularly for high glycemic index foods.
Methods
Animal housing conditions. Adult male Wistar rats (230–280 g, Charles 
River) were housed in single cages and maintained under a controlled 
environment (temperature 21°C–23°C, 12-hour light/12-hour dark 
cycle, lights on at 07:00 hours), with ad libitum access to chow (RM1; 
SDS Diets) and water, except where stated.
Glucokinase plasmid construction. Full-length glucokinase cDNA 
was isolated and amplified by PCR from pCMV4.GKB1 encoding 
full-length glucokinase cDNA (gift from Mark Magnuson, Vanderbilt 
University Medical Center, Nashville, Tennessee, USA) and cloned 
into pTR-CGW (gift from Joost Verhaagen, Nederlands Herseninsti-
tuut, Amsterdam, The Netherlands) (63).
rAAV production. rAAV was produced, isolated, and purified as 
described previously (63). The titer for rAAV-EGFP was 5.04 × 1012 
genome particles per ml, that for rAAV-GK was 2.96 × 1012 genome 
particles per ml, and that for rAAV-ASGK was 3.42 × 1012 genome 
particles per ml.
rAAV microinjections. Animal surgical procedures and handling 
were carried out as previously described (63). 1 μl of either rAAV-GK 
or rAAV-GFP was stereotaxic injected according to coordinates of 
Paxinos and Watson (64) (3.4 mm caudal, ± 0.5 mm lateral to the bre-
gma, and 9.5 mm below the surface of the skull).
Starting body weights for studies with normal chow were as fol-
lows: iARC-GFP, 270.08 ± 3.04 g, and iARC-GK, 273.60 ± 2.75 g. 
Starting body weights for long-term studies with normal chow and 
10% w/v glucose were as follows: iARC-GFP, 428.63 ± 11.58 g, and 
iARC-GK, 449.25 ± 5.60 g. Acute 24-hour normal chow and sugar 
intake feeding studies commenced at lights out (19:00 hours). Rats 
were killed during the early light phase by decapitation. Hypo-
thalami, whole brains, and weighed interscapular BAT were col-
lected and stored at –70°C. Correct targeting of rAAV to the arcuate 
nucleus was confirmed experimentally in several ways. Brains from 
one group of animals (n = 15) injected with rAAV-GK were subject 
to in situ hybridization to detect glucokinase and assessed for local-
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over baseline in response to 56 mM KCl were used in the analysis. 
At the end of each incubation period, supernatants were removed 
and tested for NPY or α-MSH release by radioimmunoassay, as 
described previously (74, 75).
Statistics. Results are shown as mean and SEM. A generalized esti-
mating equation was used to compare cumulative data between con-
trol and treatment groups. Data from glucokinase activity assays and 
calcium channel blocker and NPY antagonist studies were analyzed 
using 1-way analysis of variance, followed by post-hoc Holm-Sidak 
test. A paired Student’s t test was used to compare food intake and 
glucose intake data from crossover studies. An unpaired 2-tailed Stu-
dent’s t test was used to compare all other data. Significance was set at 
P < 0.05 for all analyses.
Study approval. All animal experiments were approved by the 
home office under the United Kingdom Animals (Scientific Proce-
dures) Act 1986 (70/7229).
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at 4°C. Glucokinase activity was determined spectrophotometrically 
using an NADP+-coupled assay with glucose-6-phosphate dehydroge-
nase. Twenty microliters of homogenate was added to 1 ml reaction 
reagent containing 100 mM GlyGly, 45 μM 5-thio-d-glucose-6-phos-
phate, 1 M MgCl2, 0.5 mM 3-O-methyl-N-acetylglucosamine, 200 
mM ATP, 12.5 mM NADP, 2 M glucose, and 0.4 units glucose-6-phos-
phate dehydrogenase (type IX, from Baker’s yeast). Each reaction was 
undertaken in triplicate. The reaction was incubated at 37°C for 1 hour. 
Absorbance at 340 nm was measured and compared with a standard 
curve for glucokinase. Sample protein concentration was determined 
by BCA protein assay (Pierce).
AMPK activity assay. AMPK assays on hypothalami were under-
taken as described previously (25).
In situ hybridization. In situ hybridization using antisense glucok-
inase cDNA riboprobe corresponding to nucleotides 15–116 of rat glu-
cokinase was performed on 15-μm frozen brain sections.
Hormone and glucose assays. Plasma insulin and leptin concen-
trations were determined by enzyme-linked immunosorbent assay 
(Crystal Chem), and plasma glucose was determined by a glucose oxi-
dase assay kit (Randox) using the manufacturer’s protocol.
Body composition. Body composition was calculated as previously 
described (72).
Quantitative PCR. Quantitative PCR was performed on hypotha-
lamic cDNA using TaqMan Gene Expression Assays (primer assay ID: 
glucokinase Rn00561265_m1, Ampk Rn00576935, Acc Rn01456589_
m1, Fas Rn01463550_m1, 18S 4310893E). mRNA expression relative to 
housekeeping gene (18S) was calculated according to the ΔΔCT method.
Northern blot. Expression of Ucp1 mRNA in interscapular BAT was 
measured by Northern blot with normalization to oligo dT.
Hypothalamic explant static incubation system. The static incu-
bation system used was a modification of the method previously 
described to measure neurotransmitter release from hypothalamic 
explants in response to glucose or pharmacologic agents (57, 73). 
Following a 2-hour equilibration period in aCSF, hypothalamic 
explants were incubated for 45-minute periods in 600 μl aCSF con-
taining 3, 8 (baseline), and 15 mM glucose in randomized order for 
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